Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) has been upgraded to Hold in a report by Zacks Investment Research today.
- Updated: September 16, 2016
Boasting a price of $5.64, Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) traded 0.64% lower on the day. The last stock close is down 17.30% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same time. AGLE has been tracking to a 50-day average of $5.81 and 200-day average of $6.57. Trade volume was was up over the average, with 63,319 shares of AGLE changing hands over the typical 38,092 shares.
Zacks Investment Research has upgraded Aeglea Bio Therapeutics Inc(NASDAQ:AGLE) to Hold in a statement released 8/17/2016.
See Chart Below:
A total of 3 firms have released a ratings update on AGLE. Zero rate the company a strong buy, 0 rate the company a buy, 0 firms rate the company a hold, 0 rate the stock to underperform, and finally 0 firmsrate the company as sell with an average target of $16.33
Aeglea Bio Therapeutics Inc has a 52 week low of $3.89 and a 52 week high of $12.75. AGLE’s market cap is currently $0.0.
General Company Details For Aeglea Bio Therapeutics Inc (NASDAQ:AGLE)
Aeglea BioTherapeutics, Inc. is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood. Its portfolio of products include AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat extremes of arginine metabolism, and including arginine excess in patients with Arginase I deficiency. AEB1102 is in Phase I clinical trial in oncology. AEB3103 is an enzyme that degrades the amino acids cysteine/cysteine. AEB2109 is an enzyme that degrades the amino acid methionine to target methionine dependent cancers. AEB4104 is an engineered human enzyme to target the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.